Axsome Therapeutics
AXSM
260 hedge funds and large institutions have $3.09B invested in Axsome Therapeutics in 2024 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 96 increasing their positions, 75 reducing their positions, and 26 closing their positions.
73% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 26
28% more repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 75
7% more funds holding
Funds holding: 244 → 260 (+16)
1% less capital invested
Capital invested by funds: $3.12B → $3.09B (-$30.4M)
1.03% less ownership
Funds ownership: 82.88% → 81.84% (-1%)
25% less call options, than puts
Call options by funds: $49.5M | Put options by funds: $66.4M
31% less funds holding in top 10
Funds holding in top 10: 13 → 9 (-4)
Top Buyers
Top Sellers
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$158M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$38.5M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
-$29.1M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
-$25.5M |
| 5 |
Morgan Stanley
New York
|
-$24.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
JF
276
Jump Financial
Chicago,
Illinois
| – | -$669K | -8,400 | Closed |
|
277
Commonwealth Equity Services
Waltham,
Massachusetts
| – | -$560K | -7,041 | Closed |
|
|
PRC
278
Pearl River Capital
Niles,
Michigan
| – | -$462K | -5,806 | Closed |
|
|
GPP
279
Great Point Partners
Greenwich,
Connecticut
| – | -$395K | -4,963 | Closed |
|
|
AIM
280
Aigen Investment Management
New York
| – | -$308K | -3,866 | Closed |
|
|
AC
281
AXQ Capital
Jersey City,
New Jersey
| – | -$294K | -3,700 | Closed |
|
282
Squarepoint
New York
| – | -$203K | -2,550 | Closed |
|
|
QC
283
Quent Capital
New York
| – | -$96.5K | -1,213 | Closed |
|
|
ASN
284
Advisory Services Network
Atlanta,
Georgia
| – | -$61.3K | -770 | Closed |
|
|
BTI
285
Blue Trust Inc
Alpharetta,
Georgia
| – | -$3K | -38 | Closed |
|
|
LF
286
Lee Financial
Dallas,
Texas
| – | -$1.27K | -16 | Closed |
|
AXSM Hedge Fund Activity: Q1 2024 in Review
260 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q1 2024, worth a combined $3.09B — down 0.98% from $3.12B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new AXSM positions and 26 closed out — a net gain of 19 holders — while 96 added to existing stakes and 75 trimmed.
The largest buyer was Macquarie Group, adding an estimated $56.5M. The largest seller was BVF Inc, exiting entirely with an estimated $158M sold.
- 260 institutional investors held Axsome Therapeutics (AXSM) as of Q1 2024, up from 244 in Q4 2023.
- Funds reported $3.09B of Axsome Therapeutics stock for Q1 2024, down 0.98% quarter-over-quarter.
- 45 funds opened new Axsome Therapeutics positions in Q1 2024 and 26 closed out, a net change of +19 holders.
- The largest Axsome Therapeutics buyer in Q1 2024 was Macquarie Group, an estimated $56.5M added.
- The largest Axsome Therapeutics seller in Q1 2024 was BVF Inc, an estimated $158M sold.
Based on aggregated 13F filings for Q1 2024.